# CSA Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/csa-medical

- Industry: Medical Devices & Equipment
- Headquarters: Lexington, US
- Total disclosed funding: $106M
- Latest round: Series D (Sep 9, 2024)
- Investors on record: 10

## About

Founded in 1993 and based in Massachusetts, US, CSA Medical, Inc. develops cryotherapy devices used in surgeries and healing of diseased tissues. In September 2024, CSA Medical, Inc. raised USD 53 million in Series D funding co-led by Yonjin Venture and TVM Capital Life Science, including SV Health Investors, Intersouth Partners, First Analysis, Ascension Ventures, and Blue Heron Capital. As of 2024, the company is led by its CEO and president, Wendelin Maners.

The company’s primary product includes truFreeze® Spray Cryotherapy, which is designed to deliver controlled bursts of liquid nitrogen to targeted areas, providing treatment for conditions such as esophageal cancer, Barrett’s esophagus, and airway obstructions. The firm’s products use extreme cold to treat or palliate conditions, particularly within the esophagus and airway. In addition, CSA Medical is also developing RejuvenAir®, a therapy aimed at treating chronic bronchitis using cryotherapy to rejuvenate the airway lining.

The organization plans to use the September 2024 funding to support the approval from the U.S. Food and Drug Association (FDA) premarket approval.

## Funding rounds

- Series D, Sep 9, 2024, $53M — First Analysis, Intersouth Partners, TVM Capital Life Science, SV Health Investors, Ascension Ventures, Blue Heron Capital, Yonjin Venture
- Series C, Dec 18, 2013, $16M — First Analysis, Intersouth Partners, SV Health Investors, Ascension Ventures, Blue Heron Capital, Guide Medical Ventures, Rose Park Advisors
- Series B, Dec 15, 2011, $21M — First Analysis, Intersouth Partners, SV Health Investors, Blue Heron Capital
- Series A, Jan 25, 2011, $10M — New Markets Venture Partners
- Series A, Jun 7, 2007, $6.2M — New Markets Venture Partners

## Investors

- New Markets Venture Partners (https://capitalatlas.ai/funds/new-markets-venture-partners) — Series A
- First Analysis (https://capitalatlas.ai/funds/first-analysis) — Series B, Series C, Series D
- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Series B, Series C, Series D
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B, Series C, Series D
- Blue Heron Capital (https://capitalatlas.ai/funds/blue-heron-capital) — Series B, Series C, Series D
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series C, Series D
- Guide Medical Ventures — Series C
- Rose Park Advisors (https://capitalatlas.ai/funds/rose-park-advisors) — Series C
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series D
- Yonjin Venture (https://capitalatlas.ai/funds/yonjin-venture) — Series D